# AUTHORS

**AUTHORS (LAST NAME, FIRST NAME):** <u>Moult, Eric M.</u><sup>1, 2</sup>; Ploner, Stefan B.<sup>3, 1</sup>; Rebhun, Carl B.<sup>4</sup>; Alibhai, A. Yasin <sup>4</sup>; Lee, ByungKun<sup>1</sup>; Moreira, Carlos<sup>4</sup>; Novais, Eduardo A.<sup>4, 6</sup>; Schottenhamml, Julia<sup>1, 3</sup>; Husvogt, Lennart<sup>1, 3</sup>; Maier, Andreas K.<sup>3</sup>; Rosenfeld, Philip J.<sup>5</sup>; Duker, Jay S.<sup>4</sup>; Waheed, Nadia<sup>4</sup>; Fujimoto, James G.<sup>1</sup>

#### **INSTITUTIONS (ALL):**

1. Electrical Engineering and Computer Science, MIT, Cambridge, MA, United States.

2. Health Sciences and Technology, Harvard-MIT, Cambridge, MA, United States.

3. Pattern Recognition Lab, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.

4. New England Eye Center, Tufts Medical Center, Boston, MA, United States.

5. Ophthalmology, University of Miami Miller School of Medicine, Miami, FL, United States.

6. School of Medicine, Federal University of Sao Paulo, Sao Paulo, Brazil.

Commercial Relationships Disclosure (Abstract): Eric Moult: Commercial Relationship: Code N (No Commercial Relationship) | Stefan Ploner: Commercial Relationship: Code N (No Commercial Relationship) | Carl Rebhun: Commercial Relationship: Code N (No Commercial Relationship) | A. Yasin Alibhai: Commercial Relationship: Code N (No Commercial Relationship) | ByungKun Lee: Commercial Relationship: Code N (No Commercial Relationship) | Carlos Moreira: Commercial Relationship: Code N (No Commercial Relationship) | Eduardo Novais: Commercial Relationship: Code N (No Commercial Relationship) | Julia Schottenhamml: Commercial Relationship: Code N (No Commercial Relationship) | Lennart Husvogt: Commercial Relationship: Code N (No Commercial Relationship) | Andreas Maier: Commercial Relationship: Code N (No Commercial Relationship) | Philip Rosenfeld: Commercial Relationship(s);Carl Zeiss Meditec, Inc.:Code F (Financial Support) ;Carl Zeiss Meditec, Inc.:Code C (Consultant) Jay Duker: Commercial Relationship(s);Topcon Medical Systems, Inc.:Code F (Financial Support) ;Carl Zeiss Meditec, Inc.:Code C (Consultant) ;Optovue, Inc.:Code C (Consultant) ;Topcon Medical Systems, Inc.:Code C (Consultant) ;Carl Zeiss Meditec, Inc.:Code F (Financial Support) ;Optovue, Inc.:Code F (Financial Support) Nadia Waheed: Commercial Relationship(s);Regeneron:Code C (Consultant) ;Genentech:Code C (Consultant) ;Ocudyne:Code C (Consultant) ;Optovue, Inc.:Code R (Recipient) ;MVRF:Code F (Financial Support) ;Janssen:Code C (Consultant) ;Nidek:Code R (Recipient) ;Carl Zeiss Meditec, Inc.:Code R (Recipient) | James Fujimoto: Commercial Relationship(s);Optovue, Inc.:Code I (Personal Financial Interest) ;Carl Zeiss Meditec, Inc.:Code P (Patent) ;Optovue, Inc.:Code P (Patent) Study Group: (none)

# ABSTRACT

**TITLE:** Variable Interscan Time Analysis (VISTA-) Optical Coherence Tomography Angiography (OCTA) of Blood Flow Speeds in Eyes with Diabetic Retinopathy


# ABSTRACT BODY:

**Purpose:** The introduction of optical coherence tomography angiography (OCTA) allows clinicians to study the microvascular alterations that occur in diabetic retinopathy (DR). Standard OCTA systems yield a detailed picture of the presence of vasculature, but have limited dynamic range and provide little information about blood flow speeds. Our group has recently developed variable interscan time analysis (VISTA), which provides a framework for studying relative blood flow speeds using OCTA. This study investigates VISTA to assess microvascular blood flow speeds in eyes with DR.


**Methods:** Using a VISTA protocol we analyzed 3 eyes with mild non-proliferative DR (NPDR) (2 patients; 66.7±2.31 y/o), 5 eyes with moderate NPDR (3 patients; 57.6±16.58 y/o), 5 eyes with severe NPDR (4 patients; 51.8±13.44 y/o), and 8 eyes with proliferative DR (PDR) (6 patients; 57.0±13.38 y/o).

**Results:** We observed a range of flow distributions associated with capillary looping/microaneurysms, tortuous vessels, dilated vessels, and neovasculature vessels. Representative VISTA-OCTA images are shown in Figures 1 and 2.

**Conclusions:** VISTA is a useful framework for studying blood flow speeds in eyes with DR.



(A) 68 y/o mild NPDR eye (6x6mm field). (B) 28 y/o moderate NPDR eye (3x3mm field). (A-B).1 Color fundus photos. (A-B).2 Fluorescein angiography. (A-B).3 En face OCTA projections through the retinal vasculature. (A-B).4 VISTA-OCTA images. (A-B.3.1) Enlargements of white boxes in A-B.3. (A-B.4.1) Enlargements of white boxes in A-B.4. White arrows point to suspected capillary loops and/or microaneurysm-like features. In VISTA-OCTA images, blue vs red correspond to slower vs faster blood flow, respectively.<br/>



(A) 56 y/o severe NPDR eye (3x3mm field). (B) 65 y/o PDR eye (3x3mm field). (A-B).1 Color fundus photos. (A-B).2 Fluorescein angiography. (A-B).3 En face OCTA projections through the retinal vasculature. (A-B).4 VISTA-OCTA images. (A-B.3.1) Enlargements of white boxes in A-B.3. (A-B.4.1) Enlargements of white boxes in A-B.4. White arrows point to suspected capillary loops and/or microaneurysm-like features, red arrows point to a tortuous vessel, and orange arrows point to vessel dilation. In VISTA-OCTA images, blue vs red correspond to slower vs faster blood flow, respectively.

#### DETAILS

PRESENTATION TYPE: #1 Paper, #2 Poster CURRENT REVIEWING CODE: 1970 diabetic retinopathy: medical - RE CURRENT SECTION: Retina Clinical Trial Registration (Abstract): No Other Registry Site (Abstract): (none) Registration Number (Abstract): (none) Date Trial was Registered (MM/DD/YYYY) (Abstract): (none) Date Trial Began (MM/DD/YYYY) (Abstract): (none) Grant Support (Abstract): Yes Support Detail (Abstract): NIH 5-R01-EY011289-28, AFOSR FA9550-15-1-0473, AFOSR FA9550-10-1-0551, MVRF

# TRAVEL GRANTS and AWARDS APPLICATIONS

AWARDS: ARVO and ARVO Foundation Travel Grants|ARVO Members-in-Training Outstanding Poster Award

#### **AFFIRMATIONS**

**Affirmations:** Affirmation that submission of this abstract has been approved by the Principal Investigator. **Affirmations:** Affirmation that abstract data/conclusions have not been published; not redundant with other submissions from same investigators.

**Affirmations:** Affirmation to reveal essential structure, novel compound elements, or identify new gene compounds. **Affirmations:** Affirmation of compliance with ARVO's Statement for Use of Human Subjects and/or Declaration of Helsinki.

Affirmations: Affirmation of compliance with ARVO policy on registering clinical trials.

Affirmations: Affirmation to pay Annual Meeting's full registration fee.

Affirmations: Affirmation to present same work as abstract submission.

**Affirmations:** Affirmation of copyright transfer from each author to ARVO, or certification of public domain abstract. **Affirmations:** Affirmation of compliance with ARVO's Statement for Use of Animals.